Intervention

Cannabidiol (CBD)

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting1

Common conditions10

Lead sponsors shown4

Clinical trials

4 shown

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain PhenotypeNCT05269628 · 2022-03-25

RECRUITING

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset PsychosisNCT03883360 · 2050-01-01

WITHDRAWN

Stratification and Treatment in Early Psychosis Study - PROMOTENCT07434973 · 2026-05-01

NOT_YET_RECRUITING

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated ArthralgiasNCT04754399 · 2021-04-16

COMPLETED

Common conditions

Arthralgia1 Breast Cancer1 Cannabis Use1 Clinical High Risk for Developing Psychosis1 Clinical High Risk for Psychosis1 Clinical High Risk for Psychosis (CHR)1 Multiple Sclerosis1 Pain1 Schizophrenia Spectrum Disorders1 Sleep1

Leading sponsors

Tiffany J. Braley, MD, MS 1 University of Maryland, Baltimore 1 University of Michigan Rogel Cancer Center 1 University of Oxford 1

Trial status mix

COMPLETED1

NOT_YET_RECRUITING1

RECRUITING1

WITHDRAWN1

Phase mix

PHASE23

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.